The repurposed STAT3 inhibitor pyrimethamine controls mycobacterial infection-induced vascular permeability and mycobacterial burden
Darryl JY Han, Xiangyu Sui, Sakshi Agarwal, Ria Sorayah, Amit Singhal, Luke H. Hoeppner, Stefan H. Oehlers
The paper shows pyrimethamine, an FDA-approved drug, reduces vascular permeability and mycobacterial burden in a zebrafish infection model by inhibiting bacterial dihydrofolate reductase and restoring vascular barrier function.
Biomedicine & Pharmacotherapy · Aug 12, 2025Peer-reviewedMicrobiology